Brenda Ginos

Mayo Clinic

Papers

1

Total Citations

19

H-Index

1

About

Brenda Ginos is a leading clinical researcher in the field of head and neck oncology, with a specific focus on de-escalation strategies for human papillomavirus (HPV)-positive oropharyngeal cancer. Her major contribution centers on optimizing treatment protocols to reduce long-term toxic effects while maintaining excellent cure rates. In her highly cited 2022 study, "Long-Term Toxic Effects, Swallow Function, and Quality of Life on MC1273," Ginos investigated a dose de-escalation approach combining transoral robotic surgery with reduced adjuvant chemoradiation. This phase 2 trial demonstrated that carefully selected patients could achieve favorable outcomes with significantly less treatment burden, preserving swallow function and quality of life. With 19 citations, this work has influenced ongoing clinical trials and treatment guidelines. Ginos’s research addresses a critical challenge in oncology: balancing curative intent with survivorship quality. Her findings offer hope for reducing the debilitating side effects that often accompany standard therapy, marking her as a key voice in the movement toward personalized, less toxic cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
19
Total Citations
19
Avg Citations/Paper
🏆 Most Cited Paper
Long-Term Toxic Effects, Swallow Function, and Quality of Life on MC1273: A Phase 2 Study of Dose De-escalation for Adjuvant Chemoradiation in Human Papillomavirus-Positive Oropharyngeal Cancer
19 citations · 2022
📈 Most Prolific Year: 2022 (1 Papers)
🤝 Key Collaborators: 14
🏛 Institutions: Mayo Clinic

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 14 days ago